2016 ASCO Annual Meeting Slide show
Read More
James R. Perry, MD, FRCPC, presenting abstract LBA2, A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). during Plenary Session including Science of Oncology Award and Lecture
Chicago, IL - 2016 ASCO Annual Meeting - James R. Perry, MD, FRCPC, presenting abstract LBA2, A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). during Plenary Session including Science of Oncology Award and Lecture at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Sunday June 5, 2016. Over 30,000 physicians, researchers and healthcare professionals from over 100 countries are attending the 52nd Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Brian Powers 2016 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org
